Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) PT at $7.00

Key Points

• Milestone Pharmaceuticals Inc. has received a consensus recommendation of "Hold" from five research firms, with three analysts assigning a hold rating and two a buy rating.
• The average 12-month target price set by brokers for Milestone Pharmaceuticals is $7.00, despite the stock currently trading at $1.49.
• Recent institutional investments in Milestone Pharmaceuticals include a significant 553.5% increase in stakes by Valeo Financial Advisors, now owning 130,699 shares valued at $254,000.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.00.

Separately, HC Wainwright upgraded shares of Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price on the stock in a report on Thursday, June 5th.

Milestone Pharmaceuticals Stock Down 1.7%

MIST stock traded down $0.03 during trading on Tuesday, hitting $1.49. 294,882 shares of the stock traded hands, compared to its average volume of 1,767,179. The company has a debt-to-equity ratio of 4.06, a current ratio of 4.67 and a quick ratio of 4.67. The stock has a market cap of $79.39 million, a price-to-earnings ratio of -1.90 and a beta of 0.52. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.75. The firm's 50 day moving average is $1.72 and its two-hundred day moving average is $1.62.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. National Bank of Canada FI boosted its position in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after purchasing an additional 11,600 shares during the period. XTX Topco Ltd purchased a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at $80,000. Northern Trust Corp boosted its holdings in Milestone Pharmaceuticals by 112.6% in the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after buying an additional 30,772 shares during the period. Boxer Capital Management LLC purchased a new stake in Milestone Pharmaceuticals in the 4th quarter worth $729,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Milestone Pharmaceuticals in the 4th quarter worth $73,000. Institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.